3D Global Biotech Inc.
3D Global Biotech Inc. develops medical materials for human body reconstruction in China. It uses cell culture systems, 3D printing technology, and bio-inks hydrogel as the basis to develop and produce customized autologous cell-based medical products. The company develops human tissue and organ reconstruction platforms; develops customized and personalized medical equipment; and conducts profess… Read more
3D Global Biotech Inc. (6808) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.087x
Based on the latest financial reports, 3D Global Biotech Inc. (6808) has a cash flow conversion efficiency ratio of 0.087x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$78.32 Million) by net assets (NT$905.47 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
3D Global Biotech Inc. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how 3D Global Biotech Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
3D Global Biotech Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 3D Global Biotech Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Daehan Steel
KO:084010
|
0.015x |
|
DR.Wu Skincare Co Ltd
TWO:6523
|
0.154x |
|
Tonymoly Co Ltd
KO:214420
|
0.032x |
|
AGROB Immobilien AG
F:AGR3
|
N/A |
|
Reinet Investments SCA
JSE:RNI
|
0.000x |
|
Seacon Shipping Group Holdings Limited
F:K2N
|
N/A |
|
Tien Giang Investment and Construction JSC
VN:THG
|
N/A |
|
iBio, Inc. Common Stock
NASDAQ:IBIO
|
-0.093x |
Annual Cash Flow Conversion Efficiency for 3D Global Biotech Inc. (2019–2024)
The table below shows the annual cash flow conversion efficiency of 3D Global Biotech Inc. from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$904.69 Million | NT$19.65 Million | 0.022x | +120.16% |
| 2023-12-31 | NT$293.47 Million | NT$-31.61 Million | -0.108x | -6.39% |
| 2022-12-31 | NT$340.60 Million | NT$-34.49 Million | -0.101x | -9.64% |
| 2021-12-31 | NT$389.71 Million | NT$-35.99 Million | -0.092x | -78.45% |
| 2020-12-31 | NT$448.82 Million | NT$-23.23 Million | -0.052x | -46.64% |
| 2019-12-31 | NT$499.80 Million | NT$-17.64 Million | -0.035x | -- |